These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11224694)

  • 1. Dyslipidemia and renal disease: pathogenesis and clinical consequences.
    Wanner C; Quaschning T
    Curr Opin Nephrol Hypertens; 2001 Mar; 10(2):195-201. PubMed ID: 11224694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.
    Quaschning T; Krane V; Metzger T; Wanner C
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S14-9. PubMed ID: 11576915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid changes and statins in chronic renal insufficiency and dialysis.
    Wanner C; Krane V; Metzger T; Quaschning T
    J Nephrol; 2001; 14 Suppl 4():S76-80. PubMed ID: 11798151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
    Le Goff W; Guerin M; Chapman MJ
    Pharmacol Ther; 2004 Jan; 101(1):17-38. PubMed ID: 14729390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherogenic lipoproteins in end-stage renal disease.
    Shoji T; Ishimura E; Inaba M; Tabata T; Nishizawa Y
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S30-3. PubMed ID: 11576918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Association of atherosclerosis and nephropathy in diabetes mellitus. Role of lipid anomalies].
    Picard S; Borson-Chazot F; Berthezène F
    Presse Med; 1991 Oct; 20(34):1672-6. PubMed ID: 1836572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormalities in lipoprotein metabolism in hemodialysis patients.
    Königer M; Quaschning T; Wanner C; Schollmeyer P; Krämer-Guth A
    Kidney Int Suppl; 1999 Jul; 71():S248-50. PubMed ID: 10412790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.
    Shoji T; Nishizawa Y; Kawagishi T; Tanaka M; Kawasaki K; Tabata T; Inoue T; Morii H
    Atherosclerosis; 1997 Jun; 131(2):229-36. PubMed ID: 9199276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of dyslipidemia in end-stage renal disease.
    Prichard SS
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S315-20. PubMed ID: 12939388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atherogenicity of triglyceride-rich lipoproteins.
    Krauss RM
    Am J Cardiol; 1998 Feb; 81(4A):13B-17B. PubMed ID: 9526808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis.
    Olofsson SO; Borèn J
    J Intern Med; 2005 Nov; 258(5):395-410. PubMed ID: 16238675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome.
    Grundy SM
    Am J Cardiol; 1998 Feb; 81(4A):18B-25B. PubMed ID: 9526809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein heterogeneity and apolipoprotein B metabolism.
    Packard CJ; Shepherd J
    Arterioscler Thromb Vasc Biol; 1997 Dec; 17(12):3542-56. PubMed ID: 9437204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
    Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uremia-specific alterations in lipid metabolism.
    Wanner C; Krane V
    Blood Purif; 2002; 20(5):451-3. PubMed ID: 12207090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis.
    Yiğitoğlu MR; Polat MF; Akçay F; Ari Z; Uyanik BS; Ozilgili HM
    Jpn Heart J; 1997 Jan; 38(1):83-9. PubMed ID: 9186284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of non-LDL:non-HDL particles in atherosclerosis.
    Segrest JP
    Curr Diab Rep; 2002 Jun; 2(3):282-8. PubMed ID: 12643186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.